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The HSD11B1 gene is highly expressed in abdominal adipose tissue, and the enzyme it encodes catalyzes the
interconversion of inactive cortisone to hormonally active cortisol. Genetic abnormalities of HSD11B1 have been
associated with the development of abnormal glucose metabolism and body fat distribution. To systematically
review studies evaluating the association of HSD11B1 gene expression in abdominal adipose tissue and HSD11B1
polymorphisms with obesity, the metabolic syndrome (MetS), and type 2 diabetes (T2DM), we conducted a search
in MEDLINE, SCOPUS, and Cochrane Library databases in April 2015. The inclusion criteria were observational studies
(cross-sectional, cohort, or case–control), conducted in adults, which analyzed the relationship of HSD11B1 polymorphisms
and/or HSD11B1 expression in abdominal adipose tissue with obesity, MetS, or T2DM. Of 802 studies retrieved, 32 met the
inclusion criteria (23 gene expression and 9 polymorphism studies). Twenty one studies analyzed the relationship
between abdominal subcutaneous and/or visceral HSD11B1 expression with central and/or generalized obesity.
Most studies reported that abdominal adipose HSD11B1 expression increased with increasing body mass index
(15 studies) and abnormalities of glucose metabolism (7 studies), and varied with the presence of MetS (3
studies). Nine studies analyzed the association of 26 different HSD11B1 polymorphic variants with obesity, MetS,
and T2DM. Only an Indian study found an association between a polymorphic variant at the HSD11B1 gene with
MetS whereas in Pima Indians another polymorphic variant was found to be associated with T2DM. While the
literature suggests that HSD11B1 is hyperexpressed in abdominal adipose tissue in subjects with obesity and
abnormal glucose metabolism, this seems to be not true for HSD11B1 gene expression and MetS. Although an
association of polymorphic variants of HSD11B1 with MetS in Indians and in the T2DM population of Pima Indians
were found, most studies did not find a relationship between genetic polymorphic variants of HSD11B1 and
obesity, MetS, and T2DM. Their reported conflicting and inconclusive results, suggesting that polymorphic
variants of HSD11B1 may have only a small role in the development of metabolic abnormalities of susceptible
populations in the development of MetS and T2DM.
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Hydroxysteroid (11-beta) dehydrogenase type 1 (11-
βHSD1) is a bidirectional enzyme, encoded by the
HSD11B1 gene, that is highly expressed in liver and
adipose tissue. It normally converts the inactive hor-
mone cortisone into its active form cortisol, acting as
a reductase [1].
Overexpression of the HSD11B1 gene in adipocytes
has been shown to be related to high cortisol concentra-
tions in adipose tissue and to the development of central
obesity, insulin resistance (IR), and diabetes in mouse
models [2]. On the other hand, HSD11B1 knockout mice
exposed to a high fat diet are protected against the de-
velopment of obesity and hyperglycemia [3]. Moreover,
11-βHSD1 inhibitors have been shown to be effective in
treating different aspects of the metabolic syndrome
(MetS), promoting weight loss and reducing IR and
hyperglycemia.
Cushing’s syndrome, which is caused by excess gluco-
corticoid production, has clinical features that resemble
those of MetS in several aspects, suggesting that they
share possible pathogenic pathways which result in their
metabolic abnormalities. As overexpression of HSD11B1
in abdominal adipose tissue is associated with increased
adipose tissue cortisol concentrations, polymorphic vari-
ants of this gene may be related to MetS development [4].
To elucidate this issue, we conducted a systematic re-
view of the literature addressing the potential associ-
ation of HSD11B1 polymorphic variants and abdominal
HSD11B1 adipose tissue expression with MetS, type 2
diabetes mellitus (T2DM), and obesity.
Methods
The Preferred Reporting Items for Systematic Reviews
and Meta-Analysis (PRISMA) statement was used in this
report. This systematic review is registered in PROSPERO
with number CRD42014008705 and can be assessed on
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?
ID=CRD42014008705#.VQmwC9LF9A0.
Search strategy, study selection, and data extraction
Observational studies (cross-sectional, cohort, or case–con-
trol) which have analyzed the relationship of polymor-
phisms and/or HSD11B1 gene expression with obesity,
MetS, or T2DM in human adults were considered eligible.
Exclusion criteria were: subjects under 18 years, the pres-
ence of malignancy, infectious diseases or diseases that may
affect HSD11B1 gene expression or was described to be as-
sociated with its polymorphic variants such as Cushing’s
syndrome, osteoporosis, cortisone reductase deficiency
(CRD), Alzheimer’s disease and polycystic ovary syndrome
(PCOS). A literature search was performed in MEDLINE,
Cochrane Central, and Scopus databases. We also manually
searched the references of published studies. Studyselection was not limited by language. The search strat-
egy was based on the following Medical Subject Head-
ings (MeSH): ((((“Obesity“[Mesh]) OR ”Diabetes
Mellitus, Type 2”[Mesh]) OR “Prediabetic State”[-
Mesh])) AND (“11-beta-Hydroxysteroid Dehydrogenase
Type 1”[Mesh]).
Study selection was performed by two independent in-
vestigators (FVN and VP). Disagreements were resolved
by discussion and consensus; when necessary, a third re-
viewer (FG) was consulted. Data was extracted by two
investigators (FVN and VP) using a standardized form.
The information extracted from each individual study
was as follows: design, ethnicity, polymorphisms geno-
typed, tissue site for biopsy and gene expression analysis,
number of individuals in each group, gender distribu-
tion, body mass index (BMI), waist circumference, waist-
to-hip ratio, and fasting and 2-h plasma glucose levels
after a 75-g oral glucose tolerance test. The Newcastle–
Ottawa Scale (NOS) was used to assess the quality of
the selected studies [5]. The NOS contains eight items
categorized into three dimensions, including selection,
comparability, and exposure. A series of response op-
tions is provided for each item. A star scoring system is
used to allow semi quantitative assessment of study
quality, such that the highest-quality studies are awarded
a maximum of one star for each item, except on the
comparability item, for which two stars can be assigned.
The total NOS score thus ranges from zero to nine stars.
Results
Our search strategy yielded 802 records (Figure 1). On
the basis of titles and abstracts, we selected 71 studies
for full-text examination, of which 32 fulfilled the final
inclusion criteria. Studies were grouped according to the
relationship they set out to assess: 1) HSD11B1 gene ex-
pression in subcutaneous/visceral abdominal fat and
MetS [6-8]; 2) HSD11B1 gene expression in subcutane-
ous/visceral abdominal fat and hyperglycemia [6,8-14];
3) HSD11B1 gene expression in subcutaneous/visceral
abdominal fat and obesity [4,6-11,13,15-28]; 4) HSD11B1
polymorphisms and obesity, MetS, or T2DM [29-37].
The main results of these studies are presented in
Tables 1, 2, 3 and 4. The mean quality score was 5.31
stars, and the details of quality assessment were de-
scribed in Table 5.
Relationship between HSD11B1 expression in
subcutaneous and visceral abdominal fat and the
metabolic syndrome
Three studies compared the expression of HSD11B1 in
adipose tissue according to the presence of MetS [6-8]
(Table 1). These studies included a total of 121 partici-
pants (mean age, 41.7 years). Two of them recruited only
obese subjects, whereas the third compared obese vs.
Figure 1 Study selection flow diagram.
do Nascimento et al. Diabetology & Metabolic Syndrome  (2015) 7:38 Page 3 of 13lean control subjects; two studies recruited subjects with
a predominant female population, whereas one included
only women. HSD11B1 expression was quantified as
arbitrary units using similar methodology (RT-qPCR),
differing primarily in their housekeeping genes (GUSB,
TBP and 18S). Prevalence of T2DM was low and var-
ied between 7.4 and 19.4%. In the first study [6],
HSD11B1 expression in abdominal subcutaneous adi-
pose tissue (SAT) was higher in 62 obese subjects with
MetS compared to those without MetS, whereas ex-
pression in abdominal visceral adipose tissue (VAT)
was similar between groups. Contrasting with these
findings, another study with 32 obese individuals (six
with T2DM) [8] found that HSD11B1 expression was
not significantly higher in either abdominal SAT or
VAT in subjects without MetS compared to those with
MetS. On the other hand, in a case–control study,
HSD11B1 expression in abdominal VAT was signifi-
cantly higher in 19 obese women (two with T2DM)
than in eight lean women [7] (Table 1).Relationship between HSD11B1 expression in subcutaneous
and visceral abdominal fat and hyperglycemia
Eight studies analyzed the relationship between HSD11B1
expression in abdominal SAT and VAT with estimates of
insulin resistance, β-cell function, blood glucose levels
and abnormalities of glucose metabolism and T2DM,
in populations of different ethnic background, includ-
ing Caucasians, African Americans, Pima Indians, His-
panic Americans and populations from Sweden and
Denmark (data not clear about ethnicity) (Table 2).
One study included only women [11] and seven studies
included both genders, mostly women in 6 and mostly
men in one [6,8-10,12-14]. The prevalence of T2DM
varied between 0 and 22.4% among studies, with two
studies where this information was not provided. These
differences in gender distribution among studies do not
affect the results of these findings. While HSD11B1
VAT expression increased respectively with increasing
fasting plasma glucose [9] and HOMA-IR [10] in mor-
bid obese subjects of two different studies, two have
Table 1 Relationship between HSD11B1 gene expression in abdominal adipose tissue and the metabolic syndrome:
studies and subjects’ characteristics
Author, year Subjects’ characteristics T2DM Obesity BMI (kg/m2) MetS Expression in VAT (AU) Expression in SAT (AU)
Alberti, 2007 [6] n: 62
12 (19.4) 62 (100.0) 37.4 ± 5.1 25 (40.3) MetS+: 2.6 ± 0.5 MetS+: 2.0 ± 1.5Female: 52 (83.9)
Age: 44.4 ± 11.1 MetS-: 1.7 ± 1.0 MetS-: 0.7 ± 0.4a
Ethnicity: N/D
Muñoz, 2009 [8] n: 32
6 (18.8) 32 (100.0) 36.7 ± 3.8 16 (50.0) MetS+: 7.5 MetS+: 11.6Female: 21 (65.6)
MetS-: 10.3 MetS-: 12.3Age: 40.2 ± 12.3
Ethnicity: N/D
Michalaki, 2012 [7] n = 27
2 (7.4) 19 (70.4) 46.1 ± 6.6 11 (40.7) Lean controls: 27.8 ± 16.0 MetS+: 86.5 ± 29.8
MetS+: 62.9 ± 24.4
MetS-: 107.2 ± 77.7b
MetS-: 155.9 ± 124.9
Female: 27 (100)
Age: 37.3 ± 9.7
Ethnicity: N/D
Data expressed as absolute and relative frequencies or mean ± standard deviation as appropriate. T2DM: type 2 diabetes mellitus; BMI: body mass index; MetS:
metabolic syndrome; VAT: visceral adipose tissue; SAT: subcutaneous adipose tissue; AU: arbitrary units; N/D: not described. aP < 0.01 vs. MetS+ group. bP < 0.01
vs. lean controls.
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While comparing the expression of abdominal SAT
HSD11B1 according to glucose tolerance, additional
studies have shown that this expression was greater
respectively in those with T2DM (1.8 ± 0.7 vs. 1.1 ±
0.4 AU; P < 0.05) [6] and those with impaired glucose
tolerance (0.5 ± 0.06 vs. 0.29 ± 0.03 AU; P < 0.005) com-
pared with normal controls [14]. Although in another
study, increased abdominal SAT HSD11B1 expression
was related with decreased beta-cell function
(r = −0.574) estimated by the disposition index while
adjusting for different confounders, this relationship
became not significant after the inclusion of hepatic fat
fraction in the multivariate model [12]. Finally, one
study showed a trend toward increased expression of
HSD11B1 in abdominal SAT in subjects with T2DM
compared to normal controls, although the statistical
significance of this comparison was not shown due to
the small number of subjects with T2DM (n = 6) [8].
Relationship between HSD11B1 expression in
subcutaneous and visceral abdominal fat and obesity
Twenty one studies assessed the potential relationship
of HSD11B1 expression in subcutaneous and visceral
abdominal fat with obesity (Table 3). Six studies did not
find a relationship between HSD11B1 expression in ab-
dominal SAT or VAT and central or generalized obesity
[6,7,9,10,24,26]. Conversely, in two studies [15,17],abdominal SAT and VAT HSD11B1 expression was
higher in obese women than in lean women. Similar
results were reported in other three studies assessing
HSD11B1 expression only in abdominal SAT of female
subjects [16,18,25]. In the first of these studies [15], a
greater gene expression in abdominal SAT was also as-
sociated with a greater waist circumference and per-
centage of body fat. In two other studies, HSD11B1
gene expression was higher in the abdominal VAT of
obese subjects than in lean subjects [19,20]. In four
studies [8,11,13,27] HSD11B1 expression in abdominal
SAT was positively related with measures of body size
and central obesity, namely respectively, BMI [8,13,27]
and intra-abdominal VAT volume estimated by MRI
[11]. In other two studies [21,22], HSD11B1 expression
in abdominal SAT was higher in obese men and women
than in non-obese subjects. In another study, the
expression of HSD11B1 in abdominal VAT was higher
in obese women than in lean controls, but this relation-
ship was not assessed in men due to small sample size.
Zha et al. found abdominal VAT and SAT HSD11B1
expression higher in obese subjects than in lean controls
as well as a positive correlation between these expres-
sions with BMI [28]. Finally, in a small study sample of
women (n = 17), it was found a positive correlation
between abdominal SAT HSD11B1 expression and waist
circumference (r = 0.53; P < 0.05), but not with BMI
[23].




T2DM Obesity BMI (kg/m2) MetS Expression in VAT Expression in SAT
Lindsay, 2003 [13] n: 31
N/D N/D 35.4 ± 7.4 N/D N/D r = 0.46, P < 0.05 with
HOMA-IR
Female: 14 (45.2)
Age: 28.8 ± 7.7
Ethnicity: 12 Caucasian
19 Pima Indian
Goedecke, 2006 [11] n: 26
0 (0) N/D 27.2 ± 0.9 N/D r = −0.13, P = NS
with fasting glucose
r = 0.40, P < 0.016 with
fasting glucose
Female: 26 (100)




Alberti, 2007 [8] n: 62
12 (19.4) 62 (100.0) 37.4 ± 5.1 25 (40.3) N/D r = 0.460, P < 0.0001 with
fasting glucose
Female: 52 (83.9)
Age: 44.4 ± 11.1
Ethnicity: N/D
Tomlinson, 2008 [14] n = 101
7 (6.9) 101 (100) 34.4 ± 4.3 N/D N/D r = 0.44, P < 0.005 with
glucose AUC
Female: 66 (65.3)
Age: 48.0 ± 7.0
Ethnicity: N/D
Muñoz, 2009 [8] n: 32
6 (18.8) 32 (100.0) 36.7 ± 3.8 16 (50.0) r = −0.19, P = NS
with fasting glucose
r = 0.15, P = NS with
fasting glucose
Female: 21 (65.6)
Age: 40.2 ± 12.3
Ethnicity: N/D
Baudrand, 2010 [9] n = 49
11 (22.4) 49 (100) 42 ± 6.1 31 (63.3) r = 0.48, P = 0.005
with fasting insulin
N/DFemale: 35 (71)
Age: 42.2 ± 10.1
Ethnicity: N/D
Baudrand, 2011 [11] n = 41
6 (14.6) 41 (100) 36.5 (36.5 – 47.0) N/D r = 0.37, P = 0.025
with fasting glucose
N/DFemale: 29 (70)
Age: 41.0 (34.0 – 47.5)
Ethnicity: N/D
Gyllenhammer, 2014 [12] n = 36
N/D 36 (100) 35.2 ± 0.6 N/D N/D r = −0.574, P = 0.140 with
disposition index
Female: 23 (63.9)




Data expressed as absolute and relative frequencies or mean ± standard deviation or median (p25 – p75) as appropriate. T2DM: type 2 diabetes mellitus; BMI:
body mass index; MetS: metabolic syndrome; VAT: visceral adipose tissue; SAT: subcutaneous adipose tissue; N/D: not described; AUC: area under the curve in oral
glucose tolerance test; NS: non-significant.
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T2DM Obesity BMI (kg/m2) MetS Expression in VAT Expression in SAT
Paulmyer-Lacroix, 2002 [21] n: 30
N/D 18 (60) 33.8 ± 5.3 N/D N/D BMI < 25 kg/m2: 1.6 (HA)Female: 27 (90)
BMI ≥ 30 kg/m2: 4.0 (HA)aAge: 37.8 ± 11.2
Ethnicity: N/D
Tomlinson, 2002 [26] n: 32
0 (0) 11 (34.4) 28.1 ± 0.7 N/D BMI < 30 kg/m2: 15.5 ± 0.3
(n-fold)
BMI < 30 kg/m2: 15.5 ± 0.4 (n-fold)Female: 32 (100)
Age: 43 (28 – 65)
BMI ≥ 30 kg/m2: 14.8 ± 0.5
(n-fold)
BMI ≥ 30 kg/m2: 15.1 ± 0.5 (n-fold)
Ethnicity: N/D
Wake, 2003 [27] n: 32
0 (0) N/D 25.9 ± 0.9 N/D N/D r = 0.63 with BMIcFemale: 16 (50.0)
Age: 55.5 ± 3.0
Ethnicity: Caucasian
Lindsay, 2003 [13] n: 31
N/D N/D 35.4 ± 7.4 N/D N/D r = 0.34 with BMIaFemale: 14 (45.2)
Age: 28.8 ± 7.7
Ethnicity: 12 Caucasian
19 Pima Indian
Engeli, 2004 [16] n: 70
0 (0) 14 (20) 29.0 ± 3.1 N/D N/D BMI < 25 kg/m2: 0.5 (AU)Female: 70 (100)
BMI ≥ 25 kg/m2: 0.9 (AU)aAge: 57 ± 4
Ethnicity: Caucasian
Goedecke, 2006 [11] n: 26
0 (0) N/D 27.2 ± 0.9 N/D r = 0.35 with VAT volume r = 0.57 with VAT volumeaFemale: 26 (100)




Desbriere, 2006 [15] n: 22
0 (0) 12 (54.5) 30.2 ± 3.8 N/D BMI < 25 kg/m2: 0.5 (AU) BMI < 25 kg/m2: 0.5 (AU)Female: 22 (100)



















Table 3 Relationship between HSD11B1 gene expression in abdominal adipose tissue and obesity: studies and subjects’ characteristics (Continued)
Mariniello, 2006 [19] n: 24
N/D 8 (33.3) 34 ± 3.4 N/D BMI < 30 kg/m2: 1 (n-fold) N/DFemale: 17 (70.8)
BMI ≥ 30 kg/m2: 13 (n-fold)bAge: 42 ± 10
Ethnicity: N/D
Alberti, 2007 [6] n: 62
12 (19.4) 62 (100.0) 37.4 ± 5.1 25 (40.3) BMI ≥ 30 kg/m2: 2.1 ± 0.9
(AU)
BMI ≥ 30 kg/m2: 1.4 ± 0.8 (AU)Female: 52 (83.9)
Age: 44.4 ± 11.1
Ethnicity: N/D
Makkonen, 2007 [18] n: 20
0 (0) 10 (50) 28.7 ± 1.4 N/D N/D BMI < 25 kg/m2: 0.3 ± 0.1 (n-fold)Female: 20 (100)
BMI ≥ 25 kg/m2: 0.6 ± 0.1 (n-fold)aAge: 36.5 ± 3.5
Ethnicity: Caucasian
Michailidou, 2007 [20] n: 21
N/D N/D 32.7 ± 1.5 N/D r = 0.57 with BMIc r = 0.58 with BMIaFemale: 21 (100)
Age: 35 ± 1
Ethnicity: Caucasian
Paulsen, 2007 [22] n: 40
0 (0) 20 (50) 34.7 ± 3.8 0 (0) BMI < 30 kg/m2: 0.01
(n-fold)
BMI < 30 kg/m2: 0.01 (n-fold)Female: 20 (50)
BMI ≥ 30 kg/m2: 0.04
(n-fold)a
BMI ≥ 30 kg/m2: 0.05 (n-fold)a
Age: 41.3 ± 9.8
Ethnicity: N/D
Baudrand, 2010 [9] n = 49
11 (22.4) 49 (100) 42 ± 6.1 31 (63.3) N/D N/DFemale: 35 (71)
Age: 42.2 ± 10.1
Ethnicity: N/D
Muñoz, 2009 [8] n: 32
6 (18.8) 32 (100.0) 36.7 ± 3.8 16 (50.0) BMI ≥ 30 kg/m2: 7.8
(4.7 – 11.8)
(AU)
BMI ≥ 30 kg/m2: 11.4 (6.2 – 19.8) (AU)Female: 21 (65.6)
Age: 40.2 ± 12.3
Ethnicity: N/D
Simonyte, 2009 [24] n: 27 3 (9.7) 27 (100) 44.6 ± 4.5 N/D BMI ≥ 30 kg/m2: 11.2 ± 4.9
(AU)
BMI ≥ 30 kg/m2: 14.1 ± 6.4 (AU)
Female: 27 (100)



















Table 3 Relationship between HSD11B1 gene expression in abdominal adipose tissue and obesity: studies and subjects’ characteristics (Continued)
Zha, 2009 [28] n: 35
0 (0) 15 (50) 25.5 ± 1.5 N/D BMI < 25 kg/m2: 1.0 (AU) BMI < 25 kg/m2: 1.2 (AU)Female: 17 (49)
BMI ≥ 25 kg/m2: 1.5 (AU)c BMI ≥ 25 kg/m2: 1.5 (AU)cAge: 49.5 ± 12.5
Ethnicity: Chinese
Svendsen, 2009 [25] n: 24
N/D 16 (66.7) 30.0 ± 2.7 N/D N/D BMI < 25 kg/m2: 0.09 (0.03–0.60)
(AU)
Female: 24 (100)
BMI ≥ 25 kg/m2: 0.25 (0.09–0.84)
(AU)a
Age: 30.7 ± 4.7
Ethnicity: N/D
Simonyte, 2010 [23] n: 17
N/D 17 (100) 44.4 ± 4.4 N/D N/D r = 0.53 with WCaFemale: 17 (100)
Age: N/D
Ethnicity: N/D
Baudrand, 2011 [10] n = 41




Michalaki, 2012 [7] n = 27
2 (7.4) 19 (70.4) 46.1 ± 6.6 11 (40.7) BMI < 25 kg/m2: 27.8 ± 16
(AU)
BMI < 25 kg/m2: N/D
BMI ≥ 30 kg/m2: 81.6. ± 46.8
(AU)a
BMI ≥ 30 kg/m2: 115.7. ± 69.8 (AU)
Female: 27 (100)
Age: 37.3 ± 9.7
Ethnicity: N/D
Leyvraz, 2012 [17] n = 35
N/D 30 (85.7) 41.3 ± 4.6 N/D BMI < 30 kg/m2: 1.0 (0.6 – 1.4) (AU) BMI < 30 kg/m2: 1.0 (0.8 – 1.2) (AU)Female: 35 (100)
BMI ≥ 30 kg/m2: 2.9. (2.6 – 3.2)
(AU)c
BMI ≥ 30 kg/m2: 2.2 (2.1 – 2.3) (AU)cAge: 39.0 ± 9.0
Ethnicity: Caucasian
Data expressed as absolute and relative frequencies, median (interquartile range), or mean ± standard deviation as appropriate. T2DM: type 2 diabetes mellitus; BMI: body mass index; MetS: metabolic syndrome;



















Table 4 Relationship of HSD11B1 gene polymorphic variants with obesity, the metabolic syndrome, and diabetes:












512 (55.8) 32.7 (28 – 38) N/D rs846910 and rs12086634














SNP1 – OR = 1.64; P = 0.01
SNP5:
510 (60.8)
SNP5 (N/D, rs12086634 and
rs6752)
SNP5 – OR = 1.34; P = 0.02







N/D 29.6 ± 4.3 N/D
4478 T > G, 4437–4438insA and
10733G > C
No association with BMI, WC, HDL-c,
TG, FPG, fasting insulin, BP, HOMA-IR






N/D 22.8 ± 2.7
431
(14.3)
rs860185, −658G > A, +1930insA,
rs12086634, rs2236905, rs2298930,
rs932335 and rs6752





757 (54.0) 24.1 ± 3.0 N/D
rs45441700, rs846908, rs701950,
+1932Ginsdel, xrs932335, rs13306422,
rs6752 and +30249 T > C
No association with WHR, BMI, FPG,
HbA1c, fasting insulin, and HOMA-IR










N/D 28.9 (25.7 – 31.5) 43 (50.0) rs846910 and rs45487298
rs846910 related with ↓ HOMA-IR;
P = 0.011a
Age: 47 (40 – 53)
rs45487298 related with ↓ HOMA-IR;








Associated with MetS (OR = 6.64;
P < 0.0001)






N/D 26.5 ± 4.5 N/D rs846910 and rs12086634
rs846910 not related with BMI
and FPG
Age: N/D




Data expressed as absolute and relative frequencies, median (interquartile range), or mean ± standard deviation as appropriate. N/D: not described; T2DM: type 2
diabetes mellitus; BMI: body mass index; MetS: metabolic syndrome; WC: waist circumference; HDL-c: HDL cholesterol; TG: triglycerides; FPG: fasting plasma glucose; BP:
blood pressure; HOMA-IR: homeostatic model assessment of insulin resistance; HbA1c: glycated hemoglobin A1c; NPG: non-polymorphic group; PG: polymorphic group.
ain MetS (+) group. bin control group.
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Alberti, 2007 [6] + + + + ++ ++++++
Baudrand, 2010 [9] + + + ++ +++++
Baudrand, 2011 [10] + + + +++
Desbriere, 2006 [15] + + ++ ++++
Dujic, 2012 + + + + +++ +++++++
Engeli, 2004 [16] + + + + +++ +++++++
Franks, 2004 [30] + + + + +++ +++++++
Gandhi, 2013 [31] + + + + ++ ++++++
Goedecke, 2006 [11] + + + + ++++
Gyllenhammer, 2014 [12] + + ++ + +++++
Ku, 2009 [32] + + + + + +++ ++++++++
Leyvraz, 2012 [17] + + + +++
Lindsay, 2003 [13] + + + ++ +++++
Makkonen, 2007 [18] + + + + ++ ++++++
Mariniello, 2006 [19] + + + ++ +++++
Michailidou, 2007 [20] + + ++ ++++
Michalaki, 2012 [7] + + ++ ++++
Miyamoto, 2009 [2009] + + + + ++ ++++++
Moon, 2011 [34] + + + + + +++ ++++++++
Munoz, 2009 [8] + + ++ ++++
Nair, 2004 [35] + + + + +++ +++++++
Paulmyer-Lacroix, 2002 [21] + + + + +++ +++++++
Paulsen, 2007 [22] + + ++ ++++
Robitaille, 2004 [36] + +++ ++++
Simonyte, 2009 [24] + + ++ ++++
Simonyte, 2010 [23] + + + + ++++
Svendsen, 2009 [25] + + + + ++ ++ ++++++++
Tomlinson, 2002 [26] + + ++ ++++
Tomlinson, 2008 [14] + + ++ + +++++
Turek, 2014 [37] + + + ++ +++++
Wake, 2003 [27] + + ++ + +++++
Zha, 2009 [28] + + + + ++ ++++++
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obesity, the metabolic syndrome, and type 2 diabetes
mellitus
Nine studies analyzed the association between 26 differ-
ent HSD11B1 polymorphic variants and obesity, MetS,
and T2DM (Table 4) [29-37].
Asian populations were assessed in two studies from
South Korea [32,34], one study from Japan [33], and one
from India [31]. The first study analyzed 757 individuals
with and 644 without T2DM [32], and did not find asso-
ciations between any of four HSD11B1 polymorphisms
with T2DM or MetS. In another study, 427 individualswith and 358 without T2DM were analyzed and no rela-
tionship was found between two HSD11B1 polymorphic
variants and T2DM or MetS [34]. In an urban cohort of
3,005 Japanese individuals, seven HSD11B1 poly-
morphic variants were assessed and no association with
MetS was found [33]. Another study, conducted in 217
French-Canadian men, also failed to find any associ-
ation between HSD11B1 polymorphisms and MetS [36].
Finally, in a study of 918 Native Americans of the Gila
River Indian Community of Arizona, polymorphic vari-
ants of this gene were not associated with T2DM or
obesity [30].
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in India found a significant risk of MetS in subjects with
the HSD11B1 polymorphism rs12086634 [31]. Another
study found a significant risk of T2DM, but not of obesity,
in Pima Indians with the HSD11B1 polymorphic variants
rs846910 and rs12086634 [35]. Conversely, another study
found that polymorphism rs846910 was associated with de-
creased insulin resistance (decreased HOMA-IR) in sub-
jects with MetS, and that the rs45487298 polymorphism
was associated with similar findings in control subjects
without MetS [29]. Finally, it was shown no relationship be-
tween rs846910 with BMI or fasting plasma glucose levels
in 215 Euro-Brazilian descendants. The authors of the same
study concluded that rs12086634 was related with fasting
plasma glucose levels in women with a borderline p-value
(P = 0.06). However, the sample had limited statistical
power, there was no statistical correction for multiple com-
parisons and no clear definition of what was considered a
statistical difference in the methodology section [37].
Discussion
This systematic review included 32 studies which analyzed
the potential relationship of abdominal adipose HSD11B1
gene expression in human and its polymorphic variants
with MetS, T2DM, and obesity.
The relationship between HSD11B1 expression in ab-
dominal adipose tissue and MetS was analyzed in three
studies with distinct population profiles. They did not
point out to a relationship between abdominal SAT and
VAT HSD11B1 expression and MetS. However, they
were not well designed to answer this question since this
was not their main objectives. As a result, these studies
might not have enough power to detect differences in
HSD11B1 expression in abdominal SAT and VAT com-
paring groups of obese subjects with and without MetS
without having a lean control group for comparison, as
what happened in two of these studies. In the third study
that we were able to review, lean control subjects had a
significantly lower abdominal VAT HSD11B1 expression
than those presenting the MetS, strengthening this dir-
ection of thought. It is our opinion that this does not
mean that there is no relationship between abdominal
adipose tissue HSD11B1 and MetS. In other studies it
has been shown that a possible relationship between
HSD11B1 enzymatic activity and the MetS exists. It also
suggests that this enzymatic activity is more linked to
MetS than its enzymatic expression [13,38,39]. In an-
other study, increased omental HSD11B1 activity in
women submitted to a gynecological surgery was associated
with larger omental adipocytes, increased lipolysis and lipo-
protein lipase activity, decreased high-density lipoprotein
cholesterol and adiponectin levels, and an increased
homeostasis model assessment of insulin resistance index
compared to those with decreased omental activity of thisenzyme [38]. Additionally, HSD11B1 activity was more re-
lated with fasting glucose, insulin, BMI and waist circum-
ference than HDS11B1 expression in abdominal SAT in
Pima Indians and Caucasians [13]. Moreover, in a study
where HSD11B1 activity was indirectly studied by a ratio of
urinary cortisone to cortisol metabolites, it has been shown
a failure to down-regulate HSD11B1 activity in subjects
with diabetes compared to normal controls which might
contribute to the underlying pathogenesis of the MetS. The
lower prevalence of T2DM in the studies analyzed by us
may have biased our findings and may explain, in part, why
we were not able to find this link [39]. Therefore, no rela-
tionship between HSD11B1 gene expression in abdominal
adipocytes and MetS can be conclusively established on the
basis of the current literature.
A relationship between HSD11B1 expression in abdom-
inal adipose tissue and IR, pancreatic β-cell function, fast-
ing glucose, and T2DM were analyzed in eight studies of
populations with different ethnic backgrounds [6,8-14].
Their results have shown that increasing HSD11B1 ex-
pression in abdominal VAT and SAT is associated with IR
in 2 studies, impaired β-cell dysfunction in one study and
increased fasting plasma glucose levels in 4 studies
(Table 2). Additionally, two studies have shown that
HSD11B1 expression in abdominal SAT is greater in
those with impaired glucose tolerance and T2DM com-
pared with normal controls. Although it is not clear to de-
fine the specific compartment of abdominal adipose tissue
in which HSD11B1 expression is mostly associated with
metabolic abnormalities of glucose metabolism, these stud-
ies suggest that the expression of this gene in abdominal
SAT and VAT is related with abnormalities of glucose me-
tabolism and may play a role in the development of T2DM.
The relationship between HSD11B1 expression in ab-
dominal adipose tissue and markers of central and general
obesity was analyzed in 21 studies. While six studies did
not find any association between HSD11B1 expression in
abdominal adipose tissue and obesity, fifteen studies found
that a greater expression of this gene in VAT and/or SAT
was associated with increased BMI, waist circumference,
and body fat percentage. The summary data have shown
that HSD11B1 expression in abdominal SAT and VAT is
related with central obesity and body size. Unfortunately,
we were not able to perform a meta-analysis with the
summary of these data, since the studies varies in their
way to express BMI (absolute number, lean vs overweight
vs obesity, lean controls vs excessive weight), abdominal
compartment HSD11B1 expression (SAT, VAT or SAT +
VAT) and different methodologies to quantify this expres-
sion (hybridized area/field vs relative curve vs ΔΔct).
Our collected data suggest that HSD11B1 polymorphic
variants are not associated with MetS, obesity, or T2DM
in most studies [30,33-37]. However, in one study, two
HSD11B1 polymorphisms (rs846910 and rs12086634) in
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be associated with decreased insulin sensitivity, in-
creased plasma glucose levels, and T2DM in Pima
Indians [35]. Additionally, the rs12086634 polymorph-
ism was found to be associated with MetS in a study
conducted in India [31]. The polymorphic variant
rs846910 is located in the promoter region near exon 1
of the HSD11B1 gene. Carriers of this SNP exhibit in-
creased enzyme activity, which is in agreement with these
findings. However, rs12086634 is located in intron 3, and
carriers of this polymorphic variant exhibit decreased en-
zyme activity, which cannot be explained by our findings
regarding this SNP. Additionally, the polymorphic variant
rs846910 and another one, rs45487298 (SNP localized in
intron 3 of the HSD11B1 gene and related to decreased
enzyme expression), were associated respectively with in-
creased insulin sensitivity in subjects with and without
MetS in another study [29]. Due to the small sample size to
take in account their results (n = 86), it is necessary more
solid data to take in account these results. Additionally,
since polymorphic variants of HSD11B1 that change its
expression and activity are expected to have a major
role in modulating insulin sensitivity and adipose tissue
proliferation through regulation of intra-adipocyte cor-
tisol production, the presence of these polymorphic
variants would be expected to be associated with obes-
ity as well, which was not demonstrated in the present
review [35]. None of studies included in this review
assessed how these polymorphic variants affect HSD11B1
functionality. Since HSD11B1 activity is dependent on the
provision of NADPH by the co-localized enzyme hexose-
6-phosphate dehydrogenase (H6PD), polymorphic variants
affecting the effects of both H6PD and 11-βHSD1 may be
necessary to exert an effect on enzymatic activity, resulting
in metabolic abnormalities or a healthy metabolic profile.
Conclusions
In conclusion, our systematic review have shown that
expression of the HSD11B1 gene in intra-abdominal
adipose tissue is probably related to abnormalities of
glucose metabolism, T2DM and obesity, with consistent
findings across different studies. We were not able to find
that expression of the HSD11B1 gene in intra-abdominal
adipose tissue is related with MetS. Finally, the relation-
ship between polymorphic variants of HSD11B1 with
MetS in subjects from India and T2DM in Pima Indians,
but not in studies performed in several other populations,
suggests that HSD11B1 polymorphisms may have a small
role in the development of these metabolic abnormalities
only in these susceptible populations.
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